Skip to main content

Table 1 Patient Demographics and Baseline Characteristics in Studies A and B (Safety Population)

From: Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies

  Study A Study B
Placebo
n = 6
Navafenterol
300 μg
n = 6
Navafenterol
600 μg
n = 6
Navafenterol
900 μg
n = 6
Placebo
n = 6
Navafenterol
300 μg
n = 6
Navafenterol
600 μg
n = 6
Navafenterol
900 μg
n = 6
Age, years 41.5 (7.6) 34.0 (5.7) 44.2 (7.9) 36.5 (6.8) 35.7 (6.4) 30.0 (5.0) 32.0 (7.8) 35.5 (8.5)
Race, n (%)
 Asian 0 1 (16.7) 0 0 6 (100.0) 6 (100.0) 6 (100.0) 6 (100.0)
 Black/African American 0 0 0 1 (16.7) 0 0 0 0
 White 6 (100.0) 5 (83.3) 6 (100.0) 5 (83.3) 0 0 0 0
Ethnicity, n (%)
 Hispanic or Latino 1 (16.7) 0 1 (16.7) 0 0 0 0 0
Height, cm 179.7 (4.7) 179.7 (6.3) 174.2 (8.0) 176.8 (3.3) 168.5 (4.7) 172.0 (2.6) 172.8 (5.6) 170.8 (6.3)
Weight, kg 78.0 (11.1) 85.2 (13.2) 75.8 (5.25) 76.2 (8.4) 64.3 (5.1) 62.8 (5.3) 68.0 (9.3) 64.8 (6.2)
Body mass index, kg/m2 24.1 (2.6) 26.2 (2.3) 24.8 (3.7) 24.3 (1.8) 22.7 (2.0) 21.2 (1.3) 22.7 (2.1) 22.2 (2.4)
  1. Data are mean (standard deviation) unless otherwise specified